The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://barbarafnbt259681.wikitron.com/2048817/glp_3_retatrutide_a_comparative_analysis